Compare VanEck Rare Earth/Strategic Metals (REMX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Rare Earth/Strategic Metals vs GeneDx Holdings Corp — how do they compare? VanEck Rare Earth/Strategic Metals trades at $71.1, while GeneDx Holdings Corp trades at $61.39 (market cap $1.83B). The key difference: VanEck Rare Earth/Strategic Metals is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| REMX | WGS | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $109.53 | $167.51 |
52-Week Low | $49.22 | $34.51 |
Market Cap | — | $1.83B |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
REMX, the VanEck Rare Earth and Strategic Metals ETF, trades at $69.85, down 3.88% amid bearish technical signals. The ETF faces selling pressure with 13 bearish moving average signals against zero bullish, though oscillators show some buying opportunity with RSI readings in oversold territory. Recent news highlights ongoing geopolitical tensions around rare earth supply chains, with China's export controls and US efforts to secure critical minerals driving volatility in the sector.
The ETF offers exposure to 38 global rare earth companies but carries high volatility (~50% annualized) and significant China concentration risk. While strategic metals demand remains strong for technology and defense applications, REMX is best suited as a satellite holding for aggressive portfolios due to its specialized nature and geopolitical sensitivities.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
